|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang M, Lewinska M, Fan X, Zhu J and Yuan
ZM: PRR14 is a novel activator of the PI3K pathway promoting lung
carcinogenesis. Oncogene. 35:5527–5538. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lemmon MASJ and Schlessinger J: Cell
signaling by receptor tyrosine kinases. Cell. 141:1117–1134. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Blume-Jensen P and Hunter T: Oncogenic
kinase signalling. Nature. 411:355–365. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ullrich A and Schlessinger J: Signal
transduction by receptors with tyrosine kinase activity. Cell.
61:203–212. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Berger AH, Niki M, Morotti A, Taylor BS,
Socci ND, Viale A, Brennan C, Szoke J, Motoi N, Rothman PB, et al:
Identification of DOK genes as lung tumor suppressors. Nat Genet.
42:216–223. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Simister PC and Feller SM: Order and
disorder in large multi-site docking proteins of the Gab family -
implications for signalling complex formation and inhibitor design
strategies. Mol Biosyst. 8:33–46. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jones N and Dumont DJ: Recruitment of
Dok-R to the EGF receptor through its PTB domain is required for
attenuation of Erk MAP kinase activation. Curr Biol. 9:1057–1060.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bedirian A, Baldwin C, Abe J, Takano T and
Lemay S: Pleckstrin homology and phosphotyrosine-binding
domain-dependent membrane association and tyrosine phosphorylation
of Dok-4, an inhibitory adapter molecule expressed in epithelial
cells. J Biol Chem. 279:19335–19349. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mashima R, Honda K, Yang Y, Morita Y,
Inoue A, Arimura S, Nishina H, Ema H, Nakauchi H, Seed B, et al:
Mice lacking Dok-1, Dok-2, and Dok-3 succumb to aggressive
histiocytic sarcoma. Lab Invest. 90:1357–1364. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Crowder RJ, Enomoto H, Yang M, Johnson EM
Jr and Milbrandt J: Dok-6, a Novel p62 Dok family member, promotes
Ret-mediated neurite outgrowth. J Biol Chem. 279:42072–42081. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Grimm J, Sachs M, Britsch S, Di Cesare S,
Schwarz-Romond T, Alitalo K and Birchmeier W: Novel p62dok family
members, dok-4 and dok-5, are substrates of the c-Ret receptor
tyrosine kinase and mediate neuronal differentiation. J Cell Biol.
154:345–354. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cossins J, Liu WW, Belaya K, Maxwell S,
Oldridge M, Lester T, Robb S and Beeson D: The spectrum of
mutations that underlie the neuromuscular junction synaptopathy in
DOK7 congenital myasthenic syndrome. Hum Mol Genet. 21:3765–3775.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
An CH, Kim MS, Yoo NJ and Lee SH:
Mutational and expressional analysis of a haploinsufficient tumor
suppressor gene DOK2 in gastric and colorectal cancers. APMIS.
119:562–564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miyagaki H, Yamasaki M, Takahashi T,
Kurokawa Y, Miyata H, Nakajima K, Takiguchi S, Fujiwara Y, Mori M
and Doki Y: DOK2 as a marker of poor prognosis of patients with
gastric adenocarcinoma after curative resection. Ann Surg Oncol.
19:1560–1567. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamanashi Y, Higuch O and Beeson D:
Dok-7/MuSK signaling and a congenital myasthenic syndrome. Acta
Myol. 27:25–29. 2008.PubMed/NCBI
|
|
18
|
Okada K, Inoue A, Okada M, Murata Y,
Kakuta S, Jigami T, Kubo S, Shiraishi H, Eguchi K, Motomura M, et
al: The muscle protein Dok-7 is essential for neuromuscular
synaptogenesis. Science. 312:1802–1805. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hamuro J, Higuchi O, Okada K, Ueno M,
Iemura S, Natsume T, Spearman H, Beeson D and Yamanashi Y:
Mutations causing DOK7 congenital myasthenia ablate functional
motifs in Dok-7. J Biol Chem. 283:5518–5524. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hallock PTXC, Xu CF, Park TJ, Neubert TA,
Curran T and Burden SJ: Dok-7 regulates neuromuscular synapse
formation by recruiting Crk and Crk-L. Genes Dev. 24:2451–2461.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bergamin E, Hallock PT, Burden SJ and
Hubbard SR: The cytoplasmic adaptor protein Dok7 activates the
receptor tyrosine kinase MuSK via dimerization. Mol Cell.
39:100–109. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Inoue A, Setoguchi K, Matsubara Y, Okada
K, Sato N, Iwakura Y, Higuchi O and Yamanashi Y: Dok-7 activates
the muscle receptor kinase MuSK and shapes synapse formation. Sci
Signal. 2:ra72009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tezuka T, Inoue A, Hoshi T, Weatherbee SD,
Burgess RW, Ueta R and Yamanashi Y: The MuSK activator agrin has a
separate role essential for postnatal maintenance of neuromuscular
synapses. Proc Natl Acad Sci USA. 111:16556–16561. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ohkawara B, Cabrera-Serrano M, Nakata T,
Milone M, Asai N, Ito K, Ito M, Masuda A, Ito Y, Engel AG, et al:
LRP4 third β-propeller domain mutations cause novel congenital
myasthenia by compromising agrin-mediated MuSK signaling in a
position-specific manner. Hum Mol Genet. 23:1856–1868. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Heyn H, Carmona FJ, Gomez A, Ferreira HJ,
Bell JT, Sayols S, Ward K, Stefansson OA, Moran S, Sandoval J, et
al: DNA methylation profiling in breast cancer discordant identical
twins identifies DOK7 as novel epigenetic biomarker.
Carcinogenesis. 34:102–108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu TP, Tsai MH, Lee JM, Hsu CP, Chen PC,
Lin CW, Shih JY, Yang PC, Hsiao CK, Lai LC, et al: Identification
of a novel biomarker, SEMA5A, for non-small cell lung carcinoma in
nonsmoking women. Cancer Epidemiol Biomarkers Prev. 19:2590–2597.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Szász AM, Lánczky A, Nagy Á, Förster S,
Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A and Győrffy B:
Cross-validation of survival associated biomarkers in gastric
cancer using transcriptomic data of 1,065 patients. Oncotarget.
7:49322–49333. 2016.PubMed/NCBI
|
|
28
|
Chitale D, Gong Y, Taylor BS, Broderick S,
Brennan C, Somwar R, Golas B, Wang L, Motoi N, Szoke J, et al: An
integrated genomic analysis of lung cancer reveals loss of DUSP4 in
EGFR-mutant tumors. Oncogene. 28:2773–2783. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Müller JS, Herczegfalvi A, Vilchez JJ,
Colomer J, Bachinski LL, Mihaylova V, Santos M, Schara U, Deschauer
M, Shevell M, et al: Phenotypical spectrum of DOK7 mutations in
congenital myasthenic syndromes. Brain. 130:1497–1506. 2007.
View Article : Google Scholar : PubMed/NCBI
|
